Events

New Activities

Crimean-Congo Haemorrhagic Fever ...

20 May at 13.00 - 14.00 CET This webinar brings together leading experts to explore the evolving epidemiology, clinical ...

Register
Episode 2: Prof. Jos van der Meer

In this episode Ian Gould interviews Jos van der Meer (Emeritus Professor and former Chairman at the Department of Internal ...

Listen
Vaccines, human challenge studies and ...

Join ISAC’s Rapid Diagnostics and Biomarkers Working Group for a webinar exploring Vaccines, Human Challenge Studies and Their ...

Watch
How to get your paper published in IJAA ...

This expert-led webinar, hosted by ISAC and Elsevier, offers practical insights into publishing high quality antimicrobial research.

Watch
On demand - One Health special issue ...

To celebrate One Health Awareness Month, ISAC will host a 60-minute webinar showcasing cutting-edge research from the One Health Special ...

Watch
Living legends in infectious diseases

Listen to episode 1 of ISAC's new celebrating the individuals whose work has shaped modern infectious diseases, antimicrobial stewardship, diagnostics ...

Listen
Microscope

4th Polymyxin Conference

Presentations from the 4th International Conference on Polymyxins which ISAC was proud to have endorsed.

Polymyxins in the Era of CROs: Opportunities and Challenges
Co-Chairs: Profs Jian Li and Jing Zhang
8-10 October 2024, Suzhou, China

The conference explored the latest advancements across all major facets of the polymyxin class of antibiotics. Polymyxins are a last-line therapeutic option for treating life threatening infections caused by Gram-negative 'superbugs,' including the WHO priority pathogens Acinetobacter baumannii, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Day 1 
Welcome address  Jian Li / J. Zhang
TREATMENT OF LIFE THREATENING INFECTIONS DUE TO MDR GRAM NEGATIVE BACILLI  David Paterson
Infections Caused by MDR Gram-negative Pathogens: Chinese Perspectives Minggui Wang
Three different polymyxin products in China: Polymyxin B, colistin and colistin methanesulphonate (CMS) Jian Li
Clinical Use of Colistin Methanesulfonate (CMS) and Polymyxin B in Critically-ill Patients Visanu Thamlikitkul
Clinical use of colistin methanesulfonate in patients. Spanish perspectives  Juan-Pablo Horcajada
Clinical Use of Colistin Sulfate in Critically Ill Patients  Baiyi Chen
Clinical use of Polymyxins in critically-ill pediatrics patients  Qing Cao
Nephrotoxicity of Polymyxins in critically-ill patients: risk factors & toxicodynamics  Andrea LH Kwa
Pharmacokinetics of Polymyxins in Different Types of Patients  Gauri Rao
Pharmacokinetics/pharmacodynamics of polymyxins  Cornelia B. Landersdorfer
Selecting the Right Dose of Colistin and Polymyxin B Visanu Thamlikitkul
The right dose of colistin sulfate: Are we there yet? Miao Yan
Therapeutic Drug Monitoring of Polymyxins in patients: Spanish perspectives Sònia Luque
Therapeutic drug monitoring of polymyxins in patients Chinese perspectives Yaxin Fan
The Most Pressing Needs To Be Studied By Innovative Clinical Trials Juan-Pablo Horcajada
Overview of Adaptive and Platform Trial Designs Xiaofang Wang
Innovative Endpoints in Infectious Diseases Clinical Trials Sean W. X. Ong
The PRACTical Trial Design David Paterson
Day 2
One Health of polymyxin resistance Yang Wang
WHAT CAN WE LEARN FROM INHALED COLISTINMETHATSODIUM IN CYSTIC
FIBROSIS PATIENTS?		 Niels Høiby
Inhaled polymyxins in critically-ill patients  Ilias Karaiskos
Pharmacokinetics/Pharmacodynamics of Inhaled Polymyxins Yu-Wei Lin
Inhaled Polymyxins: Importance of Formulation and Delivery Qi (Tony) Zhou
Nebulized polymyxins for VAP: Methodological considerations and lessons
from experimental studies		 Yinggang Zhu
China Antimicrobial Surveillance Network（CHINET）  Dandan Yin
Polymyxin antimicrobial susceptibility testing & ChiCAST breakpoint  Qiwen Yang
Determination of polymyxin breakpoints underpinned by PK/PD Xingchen Bian
Difficult-to-treat Gram-negative Infections: Getting the most out of available agents by
Diagnostic Combination Platform		 Andrea LH Kwa
Combination therapy of polymyxins: PK/PD is the key Wanzhen Li
Controlled Clinical Studies of Polymyxin Combination Visanu Thamlikitkul
Clinical evaluation of polymyxin combination therapy against CRO infections Xiaohua Qin
Antibacterial Drug Discovery and Development Programs and Preclinical and Clinical Services
at NIAID		 Zuoyu Xu
Development of BRII-693 -- a novel synthetic lipopeptide for top priority MDR pathogens Yao Zhang
EVER206: Next Generation Polymyxin for the Treatment of Highly Resistant Gram-Negative Bacterial Infections Sunny Zhu
POLYMYXIN ACTIVITY AGAINST BIOFILM Niels Høiby
The story of Mcr Jian-Hua Liu
Epidemiology and evolution of colistin-resistant Enterobacterales Hui Wang
Day 3
EFFECTS OF POLYMYXIN ON BACTERIAL BIOFILM INFECTIONS: FROM LABORATORY TO CLINIC Zhijun Song
Inhalation of polymyxins: Efficacy shown within two hours using sputum smears Xiaoping Huang
EDGE OF ETERNITY Dongdong Zhao/ Chris Zhao
Present and future of intravenous colistin methanesulfonate in treating pneumonia: The shift towards nebulized colistin methanesulfonate   Luisa Sorlí
Population Pharmacokinetics and Dose Optimization of Polymyxin B in Critically Ill Burn Patients  Jun Yang
Acute kidney injury with intravenous colistin sulfate compared with polymyxin B in critically ill patients: A real-world, retrospective cohort study  Yueliang Xie